Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, February 1, 2022
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
[ Tue, Feb 01st 2022
] - WOPRAI
David Lebovitz Maintained (BPMC) at Hold with Decreased Target to $92 on, Feb 1st, 2022
David Lebovitz of Morgan Stanley, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Decreased Target from $111 to $92 on, Feb 1st, 2022.
David has made no other calls on BPMC in the last 4 months.
There are 4 other peers that have a rating on BPMC. Out of the 4 peers that are also analyzing BPMC, 0 agree with David's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with David
- Bradley Canino of "Stifel" Upgraded from Hold to Strong Buy and Decreased Target to $95 on, Tuesday, January 25th, 2022
- Andrew Berens of "SVB Leerink" Maintained at Buy with Decreased Target to $120 on, Wednesday, January 12th, 2022
- Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Increased Target to $122 on, Monday, January 3rd, 2022
- Dane Leone of "Raymond James" Maintained at Strong Buy with Increased Target to $133 on, Wednesday, November 10th, 2021
